title: High yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdown of IRF7.
abstract: Influenza is a serious public health problem that causes a contagious respiratory disease. Vaccination is the most effective strategy to reduce transmission and prevent influenza. In recent years, cell-based vaccines have been developed with continuous cell lines such as Madin-Darby canine kidney (MDCK) and Vero. However, wild-type influenza and egg-based vaccine seed viruses will not grow efficiently in these cell lines. Therefore, improvement of virus growth is strongly required for development of vaccine seed viruses and cell-based influenza vaccine production. The aim of our research is to develop novel MDCK cells supporting highly efficient propagation of influenza virus in order to expand the capacity of vaccine production. In this study, we screened a human siRNA library that involves 78 target molecules relating to three major type I interferon (IFN) pathways to identify genes that when knocked down by siRNA lead to enhanced production of influenza virus A/Puerto Rico/8/1934 in A549 cells. The siRNAs targeting 23 candidate genes were selected to undergo a second screening pass in MDCK cells. We examined the effects of knockdown of target genes on the viral production using newly designed siRNAs based on sequence analyses. Knockdown of the expression of a canine gene corresponding to human IRF7 by siRNA increased the efficiency of viral production in MDCK cells through an unknown process that includes the mechanisms other than inhibition of IFN-α/β induction. Furthermore, the viral yield greatly increased in MDCK cells stably transduced with the lentiviral vector for expression of short hairpin RNA against IRF7 compared with that in control MDCK cells. Therefore, we propose that modified MDCK cells with lower expression level of IRF7 could be useful not only for increasing the capacity of vaccine production but also facilitating the process of seed virus isolation from clinical specimens for manufacturing of vaccines.
authors.affiliation: Laboratory of Cell-based Vaccine Development, Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.
authors.forename: Itsuki
authors.initials: I
authors.lastname: Hamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takaku
authors.forename: Masato
authors.initials: M
authors.lastname: Tashiro
authors.forename: Norio
authors.initials: N
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004285:Dogs; D015723:Gene Library; D006801:Humans; D007252:Influenza Vaccines / Q000096:biosynthesis; D050839:Interferon Regulatory Factor-7 / Q000235:genetics*; D007370:Interferon Type I / Q000378:metabolism; D061985:Madin Darby Canine Kidney Cells / Q000821:virology*; D009975:Orthomyxoviridae / Q000502:physiology*; D010957:Plasmids / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D014776:Virus Cultivation; D014779:Virus Replication
chemical_list: D007252:Influenza Vaccines; D050839:Interferon Regulatory Factor-7; D007370:Interferon Type I; D034741:RNA, Small Interfering
references.citation: Nat Rev Immunol. 2006 Sep;6(9):644-58
references.pmid: 16932750
references.citation: Wien Klin Wochenschr. 1999 Mar 12;111(5):207-14
references.pmid: 10226351
references.citation: Cell. 2010 Mar 19;140(6):805-20
references.pmid: 20303872
references.citation: Science. 2006 May 12;312(5775):879-82
references.pmid: 16690858
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13093-8
references.pmid: 18725644
references.citation: J Virol. 2010 Sep;84(17):8433-45
references.pmid: 20538852
references.citation: J Virol. 2000 Dec;74(24):11566-73
references.pmid: 11090154
references.citation: J Gen Virol. 2007 Jan;88(Pt 1):71-76
references.pmid: 17170438
references.citation: Blood. 2008 Sep 1;112(5):2028-34
references.pmid: 18544685
references.citation: Vaccine. 2001 Mar 21;19(17-19):2716-21
references.pmid: 11257414
references.citation: Nat Immunol. 2009 Oct;10(10):1073-80
references.pmid: 19701189
references.citation: J Virol. 2003 Feb;77(3):2174-81
references.pmid: 12525652
references.citation: Nature. 2005 Apr 7;434(7034):772-7
references.pmid: 15800576
references.citation: Vaccine. 2002 Jan 15;20(7-8):1240-7
references.pmid: 11803087
references.citation: Influenza Other Respir Viruses. 2007 Jan;1(1):5-9
references.pmid: 19459278
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14802-7
references.pmid: 19706449
references.citation: Vaccine. 1998 May-Jun;16(9-10):960-8
references.pmid: 9682344
references.citation: J Virol. 2007 Jan;81(2):514-24
references.pmid: 17079289
references.citation: J Virol. 2004 Nov;78(21):11574-82
references.pmid: 15479798
references.citation: Cell Host Microbe. 2009 May 8;5(5):439-49
references.pmid: 19454348
references.citation: Annu Rev Immunol. 2005;23:307-36
references.pmid: 15771573
references.citation: PLoS Pathog. 2011 Jun;7(6):e1002067
references.pmid: 21695240
references.citation: Virology. 2006 Jan 5;344(1):119-30
references.pmid: 16364743
references.citation: Virology. 1998 Dec 20;252(2):324-30
references.pmid: 9878611
references.citation: Immunity. 2000 Oct;13(4):539-48
references.pmid: 11070172
references.citation: Science. 2006 Nov 10;314(5801):997-1001
references.pmid: 17038589
references.citation: Immunol Lett. 2009 Jan 29;122(1):1-11
references.pmid: 19059436
references.citation: Expert Rev Vaccines. 2009 Jun;8(6):679-88
references.pmid: 19485748
references.citation: Immunity. 2006 Sep;25(3):373-81
references.pmid: 16979569
references.citation: Cell Microbiol. 2007 Apr;9(4):930-8
references.pmid: 17140406
references.citation: Gene Ther. 2008 Apr;15(7):545-52
references.pmid: 18273055
references.citation: J Immunol. 2007 Mar 15;178(6):3368-72
references.pmid: 17339430